The popularity of Viagra initially drove a surge for the drug industry, nevertheless recent shifts present a murky scenario for investors. Lower-cost versions are eroding profits, and continued patent challenges add more risk to the equation. While some companies might still see gains from complementary offerings, the overall direction suggests … Read More